Yes they're likely using patients for R&D purposes related to approvals. Thus this isn't profitable because investment in the process isn't yet complete. We will see massive ROIC when MHRA approves DCVax as Sawston can handle 12K patients per year. That's about $2B in annual revenue. Our company has an insignificant amount of debt. Again massive return on invested capital.
News 
Market Data 
Discover 
